(REGN) Regeneron Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075
REGN: Eye, Allergy, Skin Cancer, Cholesterol, Covid
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes innovative medicines to treat a wide range of serious diseases. Its product portfolio includes EYLEA for eye conditions such as wet age-related macular degeneration and diabetic macular edema; Dupixent for atopic dermatitis and asthma; Libtayo for advanced skin cancer; Praluent for high cholesterol; REGEN-COV for COVID-19; and Kevzara for rheumatoid arthritis. The company also offers treatments for rare and infectious diseases, including Inmazeb for Ebola, ARCALYST for inflammatory syndromes, and ZALTRAP for colorectal cancer. Additionally, Regeneron has newer therapies like Evkeeza for HoFH, Ordspono for lymphomas, and Veopoz for protein-losing enteropathy. Its pipeline spans eye, allergic, inflammatory, cardiovascular, infectious, rare, and hematologic diseases, as well as cancer and pain management.
Regeneron collaborates with Mammoth Biosciences on CRISPR-based gene editing therapies and with Sonoma Biotherapeutics on engineered regulatory T-cell therapies. Founded in 1988 and headquartered in Tarrytown, New York, the company has established itself as a leader in monoclonal antibody technology and precision medicine. Its financial profile reflects strong R&D investments, with a market cap of $63.05 billion and a P/E ratio of 15.04, indicating moderate valuation relative to earnings. The stock currently trades at $563.16, below its 20-day SMA of $598.81 and 50-day SMA of $654.14, signaling short-term bearish momentum.
Additional Sources for REGN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
REGN Stock Overview
| Market Cap in USD | 66,463m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 1991-04-02 |
REGN Stock Ratings
| Growth Rating | 10.0 |
| Fundamental | 43.1 |
| Dividend Rating | 1.0 |
| Rel. Strength | -30.9 |
| Analysts | 4.16/5 |
| Fair Price Momentum | 466.29 USD |
| Fair Price DCF | 540.85 USD |
REGN Dividends
| Dividend Yield 12m | 0.12% |
| Yield on Cost 5y | 0.16% |
| Annual Growth 5y | % |
| Payout Consistency | 1.0% |
REGN Growth Ratios
| Growth Correlation 3m | -81.2% |
| Growth Correlation 12m | -82.5% |
| Growth Correlation 5y | 76.5% |
| CAGR 5y | 1.74% |
| CAGR/Max DD 5y | 0.03 |
| Sharpe Ratio 12m | 0.02 |
| Alpha | -44.45 |
| Beta | 0.638 |
| Volatility | 39.46% |
| Current Volume | 1114.2k |
| Average Volume 20d | 1137k |
As of May 02, 2025, the stock is trading at USD 590.00 with a total of 1,114,248 shares traded.
Over the past week, the price has changed by -1.63%, over one month by -4.38%, over three months by -11.41% and over the past year by -34.61%.
Partly, yes. Based on ValueRay Fundamental Analyses, Regeneron Pharmaceuticals (NASDAQ:REGN) is currently (May 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 43.05 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of REGN as of May 2025 is 466.29. This means that REGN is currently overvalued and has a potential downside of -20.97%.
Regeneron Pharmaceuticals has received a consensus analysts rating of 4.16. Therefor, it is recommend to buy REGN.
- Strong Buy: 12
- Buy: 6
- Hold: 6
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, REGN Regeneron Pharmaceuticals will be worth about 521.1 in May 2026. The stock is currently trading at 590.00. This means that the stock has a potential downside of -11.67%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 850.2 | 44.1% |
| Analysts Target Price | 1043 | 76.8% |
| ValueRay Target Price | 521.1 | -11.7% |